In addition, a trial validated that BRAF inhibitors combined with MEK inhibitors could improve the OS of metastatic MM patients with BRAF mutations [70]; so, a year later, the FDA approved Dabrafenib in combination with the MEK inhibitor Trametinib for MM treatment. This evidence concerns the gene BRAF and Miyoshi myopathy.